NDC 70121-1754 Alymsys
Bevacizumab-maly Injection, Solution Intravenous - View Dosage, Usage, Ingredients, Routes, UNII
Product Information
- 70121 - Amneal Pharmaceuticals Llc
- 70121-1754 - Alymsys
Product Packages
NDC Code 70121-1754-1
Package Description: 1 VIAL in 1 CARTON / 4 mL in 1 VIAL
NDC Code 70121-1754-7
Package Description: 10 VIAL in 1 CARTON / 4 mL in 1 VIAL
Product Details
What is NDC 70121-1754?
What are the uses for Alymsys?
What are Alymsys Active Ingredients?
- BEVACIZUMAB 100 mg/4mL - An anti-VEGF humanized murine monoclonal antibody. It inhibits VEGF RECEPTORS and helps to prevent PATHOLOGIC ANGIOGENESIS.
Which are Alymsys UNII Codes?
The UNII codes for the active ingredients in this product are:
- BEVACIZUMAB (UNII: 2S9ZZM9Q9V)
- BEVACIZUMAB (UNII: 2S9ZZM9Q9V) (Active Moiety)
Which are Alymsys Inactive Ingredients UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- TREHALOSE DIHYDRATE (UNII: 7YIN7J07X4)
- POLYSORBATE 20 (UNII: 7T1F30V5YH)
- SODIUM PHOSPHATE, DIBASIC, ANHYDROUS (UNII: 22ADO53M6F)
- SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE (UNII: 593YOG76RN)
- WATER (UNII: 059QF0KO0R)
What is the NDC to RxNorm Crosswalk for Alymsys?
- RxCUI: 2599043 - bevacizumab-maly 100 MG in 4 ML Injection
- RxCUI: 2599043 - 4 ML bevacizumab-maly 25 MG/ML Injection
- RxCUI: 2599043 - bevacizumab-maly 100 MG per 4 ML Injection
- RxCUI: 2599043 - bevacizumab-maly 25 MG/ML per 4 ML Injection
- RxCUI: 2599049 - Alymsys 100 MG in 4 ML Injection
Which are the Pharmacologic Classes for Alymsys?
* Please review the disclaimer below.
Patient Education
Bevacizumab Injection
Bevacizumab injection products are used in combination with other chemotherapy medications to treat certain types of colon and rectal cancer (cancer that begins in the large intestine), non-small cell lung cancer (NSCLC), glioblastoma (a certain type of cancerous brain tumor), renal cell cancer (RCC, a type of cancer that begins in the kidney), cervical cancer (cancer that begins in the opening of the uterus [womb]), and ovarian (female reproductive organs where eggs are formed), fallopian tube (tube that transports eggs released by the ovaries to the uterus), or peritoneal (layer of tissue that lines the abdomen) cancer. Bevacizumab (Avastin) is also used in combination with atezolizumab (Tecentriq) to treat hepatocellular carcinoma (HCC) that has spread or cannot be removed by surgery in people who have not previously received chemotherapy. Bevacizumab injection products are in a class of medications called antiangiogenic agents. They work by stopping the formation of blood vessels that bring oxygen and nutrients to tumors. This may slow the growth and spread of tumors.
[Learn More]
* Please review the disclaimer below.
[1] What is the Non-Proprietary Name? - The non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.
[2] What is the Substance Name? - An active ingredient is the substance responsible for the medicinal effects of a product specified by the substance's molecular structure or if the molecular structure is not known, defined by an unambiguous definition that identifies the substance. Each active ingredient name is the preferred term of the UNII code submitted.
[3] What kind of product is this? - Indicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.
[4] What are the Administration Routes? - The translation of the route code submitted by the firm, indicating route of administration.
[5] What is the Labeler Name? - Name of Company corresponding to the labeler code segment of the Product NDC.
[6] What is the FDA Application Number? - This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
[8] What is the Marketing Category? - Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
[9] What is the Start Marketing Date? - This is the date that the labeler indicates was the start of its marketing of the drug product.
[11] What is the Listing Expiration Date? - This is the date when the listing record will expire if not updated or certified by the product labeler.
[12] What is the NDC Exclude Flag? - This field indicates whether the product has been removed/excluded from the NDC Directory for failure to respond to FDA"s requests for correction to deficient or non-compliant submissions ("Y"), or because the listing certification is expired ("E"), or because the listing data was inactivated by FDA ("I"). Values = "Y", "N", "E", or "I".